首页> 外文期刊>European Journal of Pharmacology: An International Journal >Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.
【24h】

Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.

机译:吡格列酮对内毒素诱导的肝药物代谢酶活性以及CYP3A2和CYP2C11表达的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

It has been reported that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands ameliorate the expression of inducible nitric oxide synthase (iNOS) by endotoxin. In the present study, we investigated the effect of pioglitazone, a potent PPAR-gamma ligand, on the endotoxin-induced reduction of hepatic drug-metabolizing enzyme activity and on the down-regulation of the expression of hepatic cytochrome P450 (CYP) 3A2 and CYP2C11 proteins in rats. Endotoxin (1 mg/kg) significantly decreased hepatic drug-metabolizing enzyme activity in vivo, as represented by the systemic clearance of antipyrine and protein levels of CYP3A2 and CYP2C11 24 h after intraperitoneal injection. Pretreatment with pioglitazone (10 mg/kg, 4 times at 10-min intervals) significantly protected the endotoxin-induced decreases in the systemic clearance of antipyrine and protein levels of CYP3A2, but not CYP2C11, with no biochemical and histopathological changes in the liver. Pioglitazone alone had no effect on the systemic clearance of antipyrine and protein levels of CYP3A2 or CYP2C11. Pioglitazone significantly protected endotoxin-induced overexpression of iNOS in the liver, but not the overproduction of nitric oxide (NO) in plasma. It is unlikely that the protective effect of pioglitazone against endotoxin-induced decreases in the hepatic drug-metabolizing enzyme activity and protein levels of CYP3A2 in the liver is due to the inhibition of the overproduction of NO.
机译:据报道,过氧化物酶体增殖物激活的受体-γ(PPAR-γ)配体可改善内毒素诱导型一氧化氮合酶(iNOS)的表达。在本研究中,我们研究了有效的PPAR-γ配体吡格列酮对内毒素诱导的肝药物代谢酶活性降低以及对肝细胞色素P450(CYP)3A2和大鼠中的CYP2C11蛋白。内毒素(1 mg / kg)在体内显着降低了肝药物代谢酶的活性,表现为腹膜内注射后24小时对安替比林的全身清除率以及CYP3A2和CYP2C11的蛋白质水平。吡格列酮预处理(10 mg / kg,每10分钟间隔4次)可显着保护内毒素诱导的安替比林和CYP3A2而非CYP2C11的全身清除率和蛋白水平的降低,肝脏中无生化和组织病理学改变。单独的吡格列酮对安替比林的全身清除率和CYP3A2或CYP2C11的蛋白水平没有影响。吡格列酮显着保护内毒素诱导的肝脏中iNOS的过度表达,但不能保护血浆中一氧化氮(NO)的过度产生。吡格列酮对内毒素诱导的肝脏中肝药物代谢酶活性和CYP3A2蛋白水平降低的保护作用不太可能归因于对NO过量产生的抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号